Clinical Trial Update: Trial of the Immunogenicity, Safety, and Tolerability of rF1V Vaccine With CpG 1018® Adjuvant Compared With rF1V Vaccine in Adults 18 to 55 Years of Age [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating immunogenicity, safety, and tolerability of the rF1V plague vaccine with CpG 1018 adjuvant versus rF1V vaccine alone in adults 18 to 55…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plague
• Pneumonic Plague

Drugs mentioned

• rF1V plague vaccine with CpG 1018 adjuvant (rF1V plague vaccine with CpG 1018 adjuvant)
• rF1V plague vaccine without CpG 1018 adjuvant (rF1V plague vaccine without CpG 1018 adjuvant)

Snippet

Sponsor: Dynavax Technologies Corporation | Conditions: Plague, Pneumonic, Plague | Phase 2 | Status: COMPLETED | Results posted: 2025-07-29